Actualités

The company has a high bar for acquisitions.

Motorola Solutions is expected to announce its second-quarter results soon, and analysts predict a single-digit rise in the company’s bottom-line figure.

Northrop Grumman reported better-than-expected second-quarter earnings and raised its full-year financial guidance.

(Bloomberg) -- The biotechnology sector is stealing the US IPO market thunder from artificial intelligence-related listings, delivering standout returns as bankers line up a steady stream of summer debuts.Most Read from BloombergYemen’s Houthis to Impose Maritime Blockade on Saudi ArabiaChina AI Sensation Moonshot’s Gamble on Big Models Pays OffTrump Vows 50% Tariff on Canadian Goods Using Depression-Era LawMoonshot’s Kimi K3 May Be More About Memory Than ComputeUS Strikes Iran in Escalating Cam

Microsoft has agreed to spend billions of dollars on Mistral's computing infrastructure in Europe under a deal that will also expand distribution of the French AI startup's ‌technology through the U.S. cloud and software giant, the companies said on Tuesday. As part of the agreement, ‌Microsoft Azure customers will be able to develop software using Mistral's data centers in France, giving Microsoft more capacity in Europe and regulated industries an ​alternative to U.S.-controlled infrastructure. Mistral, meanwhile, has added its AI models called Medium 3.5 and OCR 4 to Microsoft's app builder known as Foundry.

The deal, structured as an all-stock transaction, gives Tempus control of Personalis' NeXT Personal cancer detection test

Investing.com -- The clash between pharma titans Novo Nordisk and Eli Lilly just escalated from the pharmacy counter to the courtroom. Novo Nordisk Inc. filed a lawsuit in the U.S. District Court for the District of New Jersey against Eli Lilly and Company and Lilly USA, LLC, alleging multiple violations of federal and state false advertising and unfair competition laws under the Lanham Act. The lawsuit takes aim at Lilly’s aggressive direct-to-consumer (DTC) advertising campaigns for its blockb

Microchip Technology is scheduled to post its first-quarter results soon, and analysts predict a triple-digit surge in the company’s bottom-line figure.

Two industrial giants report Q2 results on the same day, and analysts are anything but neutral between them. Before you decide which earnings announcement to watch on July 22, you need to see how these two stack up across every dimension Wall Street actually measures.

Vicor (VICR) delivered earnings and revenue surprises of +67.74% and +3.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Ozempic maker Novo Nordisk has filed a lawsuit against Eli Lilly, arguing it uses deceptive advertising to mislead consumers. The complaint accuses Eli Lilly of using outdated studies to promote its branded GLP-1 drugs, Mounjaro and Zepbound, as helping consumers lose significantly more weight on average than Novo Nordisk’s Ozempic and Wegovy.

Memory chip shortages continue to be a problem for most companies.

The first components of an ASML next-generation chipmaking tool arrived ‌at New York state's Albany NanoTech Complex on ‌Tuesday, the governor's office said. The NanoTech complex will use the tool to conduct ​research and development on future forms of chip design and manufacturing. The NanoTech facility is the only one of its kind in North America, according to NY Creates Director Dave Anderson, and ‌is similar in ⁠scope and focus to Europe's Imec, which operates in Belgium.

SpaceX’s IPO was the biggest in history, raising $75 billion at $135 a share.1 The offering sparked much excitement, with retail investors keen on buying into one of the world’s most closely watched companies. If you had invested $2,000 at the $135 IPO price, here’s how much your investment would be worth today, and why […] The post If You Invested $2K in the SpaceX IPO, How Much Do You Have Now? appeared first on SmartReads by SmartAsset.

The maker of Ozempic and Wegovy says its competitor is misleading consumers by citing outdated weight-loss data in advertisements.

The maker of Ozempic and Wegovy says its competitor is misleading consumers by citing outdated weight-loss data in advertisements.

(Bloomberg) -- Strong economic momentum is a double-edged sword for US equity traders. Solid growth is an earnings tailwind. But let it run too hot, and it turns from blessing to curse.Most Read from BloombergYemen’s Houthis to Impose Maritime Blockade on Saudi ArabiaChina AI Sensation Moonshot’s Gamble on Big Models Pays OffTrump Vows 50% Tariff on Canadian Goods Using Depression-Era LawMoonshot’s Kimi K3 May Be More About Memory Than ComputeUS Strikes Iran in Escalating Campaign After Troops K

📣 “When I look at AI itself, the amount of money being spent is huge. Will it in total pay off? Probably, just like the internet did. Will it pay off the way you expect on the timetable you expect? Definitely not.

By Maggie Fick LONDON, July 21 (Reuters) - Novo Nordisk said on Tuesday it was suing rival Eli Lilly in U.S. federal court, accusing the U.S. drugmaker of false advertising in claiming its weight-loss

A trading boom that carried most of Wall Street to record results this spring also lifted Charles Schwab’s quarterly profits by 32%. The brokerage reported second-quarter net income of $2.8 billion on Tuesday.

(Bloomberg) -- Novo Nordisk A/S is suing Eli Lilly & Co. in US federal court, claiming that Lilly’s advertising for its blockbuster obesity shot Zepbound and diabetes injection Mounjaro is misleading as competition between the two drugmakers escalates.Most Read from BloombergYemen’s Houthis to Impose Maritime Blockade on Saudi ArabiaChina AI Sensation Moonshot’s Gamble on Big Models Pays OffTrump Vows 50% Tariff on Canadian Goods Using Depression-Era LawMoonshot’s Kimi K3 May Be More About Memor

US equity futures were tracking in the green on Tuesday as traders await the latest batch of corpora

General Motors posted second-quarter net income of $1.31 billion, or $1.41 a share, with revenue rising to $48.03 billion.

Under the deal, Personalis’ minimal residual disease (MRD) test will be integrated into Tempus’ broader oncology portfolio.

The aerospace and defense company posted a profit of $1.09 billion, or $7.68 a share in the second quarter, with sales up 5% at $10.88 billion.

Novo Nordisk has accused arch-rival Eli Lilly of peddling false claims about its weight-loss products in advertising campaigns, marking the latest...

Halliburton stock declines after the oilfield services company posts slightly better-than-expected earnings but sees the war in the Middle East take its toll on business.

Automaker beats forecasts but shares move lowerGeneral Motors Co. (NYSE:GM) reported stronger-than-expected second-quarter results on Tuesday, surpassing Wall Street forecasts for both earnings and revenue while increasing its financial guidance for the second time this year.

The company recently announced some weaker-than-expected earnings and hinted at more potential trouble ahead.

Block is set to report Q2 earnings next month, and analysts expect its EPS to dip by double digits.